Analysts Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Price Target at $10.30

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have earned a consensus rating of “Moderate Buy” from the twelve analysts that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $10.30.

Several equities research analysts have issued reports on TSHA shares. Citigroup reissued an “outperform” rating on shares of Taysha Gene Therapies in a research report on Wednesday, November 5th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $13.00 price target on shares of Taysha Gene Therapies in a research note on Friday. Wall Street Zen cut Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Robert W. Baird raised their price objective on Taysha Gene Therapies from $7.00 to $12.00 and gave the stock an “outperform” rating in a report on Thursday, October 2nd. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Taysha Gene Therapies in a report on Thursday, October 30th.

Insiders Place Their Bets

In related news, insider Sukumar Nagendran sold 200,000 shares of the company’s stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $3.23, for a total transaction of $646,000.00. Following the completion of the sale, the insider directly owned 1,006,439 shares in the company, valued at $3,250,797.97. This represents a 16.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. 3.78% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Taysha Gene Therapies

Several institutional investors have recently added to or reduced their stakes in TSHA. Sender Co & Partners Inc. acquired a new stake in Taysha Gene Therapies during the 3rd quarter worth about $89,000. Vestal Point Capital LP raised its stake in shares of Taysha Gene Therapies by 83.3% in the third quarter. Vestal Point Capital LP now owns 5,500,000 shares of the company’s stock worth $17,985,000 after purchasing an additional 2,500,000 shares during the last quarter. Polar Capital Holdings Plc lifted its holdings in shares of Taysha Gene Therapies by 5.9% during the third quarter. Polar Capital Holdings Plc now owns 5,293,879 shares of the company’s stock worth $17,311,000 after purchasing an additional 293,879 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Taysha Gene Therapies by 15.0% in the third quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 111,024 shares of the company’s stock valued at $362,000 after buying an additional 14,481 shares during the last quarter. Finally, Jain Global LLC purchased a new stake in Taysha Gene Therapies in the third quarter valued at approximately $172,000. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Stock Performance

Taysha Gene Therapies stock opened at $4.15 on Friday. The company’s 50-day moving average price is $4.14 and its 200-day moving average price is $3.18. The company has a quick ratio of 10.48, a current ratio of 10.48 and a debt-to-equity ratio of 0.23. The company has a market cap of $1.14 billion, a PE ratio of -12.58 and a beta of 1.00. Taysha Gene Therapies has a twelve month low of $1.05 and a twelve month high of $5.51.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. On average, equities research analysts forecast that Taysha Gene Therapies will post -0.35 EPS for the current fiscal year.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.